TY  - JOUR
AU  - Mestres, J A
AU  - iMolins, A B
AU  - Martínez, L C
AU  - López-Muñiz, J I C
AU  - Gil, E C
AU  - de Juan Ferré, A
AU  - Del Barco Berrón, S
AU  - Pérez, Y F
AU  - Mata, J G
AU  - Palomo, A G
AU  - Gregori, J G
AU  - Pardo, P G
AU  - Mañas, J J I
AU  - Hernández, A L
AU  - de Dueñas, E M
AU  - Jáñez, N M
AU  - Murillo, S M
AU  - Bofill, J S
AU  - Auñón, P Z
AU  - Sanchez-Rovira, P
PY  - 2016
DO  - 10.1007/s12094-016-1520-2
UR  - http://hdl.handle.net/10668/10185
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. When selecting a systemic treatment, it is...
LA  - en
KW  - Chemotherapy
KW  - HER2 receptor
KW  - Hormone therapy
KW  - Metastatic breast cancer
KW  - Targeted therapies
KW  - Triple-negative tumor
KW  - Antineoplastic Agents
KW  - Breast Neoplasms
KW  - Female
KW  - Humans
KW  - Prognosis
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
TI  - Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
TY  - research article
VL  - 19
ER  -